Last reviewed · How we verify
Mexidol
At a glance
| Generic name | Mexidol |
|---|---|
| Also known as | Ethylmethylhydroxypyridine Succinate |
| Sponsor | Pharmasoft |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of Mexidol® in Stroke Therapy (PHASE3)
- Efficacy and Safety of Different Dosages of Mexidol® in Patients With Primary Open-angle Glaucoma (POAG) (PHASE2)
- MEXIDOL® Sequential Therapy of Patients With Primary Open-angle Glaucoma (POAG) (PHASE4)
- Safety and Efficacy of Sequential Therapy With Mexidol® in Patients With Chronic Cerebral Ischemia (PHASE3)
- Safety and Efficacy of Mexidol® for ADHD in Children Aged 6-12 (PHASE3)
- MEXIDOL® in the Rehabilitation Treatment of Patients With Acute Cerebral Failure (PHASE4)
- Study of Efficacy and Safety of MEXIDOL® in Ischemic Stroke Therapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |